

Regd. No.: 1834

A HEALTHCARE SERV

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:59 PM

Sample ID:

Test Description	Value(s)	Reference Range	Unit
	Lipid I	2*ofile	
Cholesterol-Total Method : Spectrophotometry	219.49	Desirable level < 200 Borderline High 200-239 High >or = 240	mg/dL
Triglycerides Method: Serum, Enzymatic, endpoint	224.59	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	mg/dL
HDL Cholesterol Method: Serum, Direct measure-PEG	45.90	Normal: > 40 Major Risk for Heart: < 40	mg/dL
LDL Cholesterol Method: Enzymatic selective protection	128.67	Optimal < 100 Near / Above Optimal 100-129 Borderline High 130-159 High 160-189 Very High >or = 190	mg/dL
VLDL Cholesterol Method: Serum, Enzymatic	44.92	6 - 38	mg/dL
CHOL/HDL Ratio Method: Serum, Enzymatic	4.78	3.5 - 5.0	
LDL/HDL Ratio Method : Serum, Enzymatic Note:	2.80	2.5 - 3.5	
8-10 hours fasting sample is required.			

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



ZENA HEALTHCARE SERVICES

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:33 PM

Sample ID:

Test Description	Value(s)	Reference Range	Unit
		250	

HbA1C, Glycosylated Hemoglobin

HbA1c (GLYCOSYLATED HEMOGLOBIN),

7.10

%

BLOOD

Method : (HPLC, NGSP certified)

Estimated Average Glucose:

mg/dL

Interpretation

Reference Group	HbA1c in %
Non diabetic adults >=18 years	<5.7
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
	Age > 19 years
Therapeutic goals for glycemic control	Goal of therapy: < 7.0
	Action suggested: > 8.0
	Age < 19 years
	Goal of therapy: <7.5

Note:

- Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently
 under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under
 good control but now poorly controlled.
- 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

ADA criteria for correlation between HbA1c & Mean plasma glucose levels.

HbA1c(%)	Mean Plasma Glucose (mg/dL)
6	126
7	154
8	183
9	212



HEALTHCARE SERV

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:33 PM


Sample ID:

Tost Pesseleti				21290	
Test Description	Value(s)	Reference Range	Unit		
10	240				
11	269				
12	298				

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST





ALTHCARE SER

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:33 PM

Sample ID:

Test Description

Value(s)

Reference Range

Unit

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



HEALTHCARE SERV

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:46 PM

Sample ID:

Reference Range Blood Count 13.5 - 18.0 4.7 - 6.0 42 - 52 78 - 100 27 - 31 32 - 36 11.5 - 14.0	gm/dL mil/cu.mm % fL pg g/dL %
13.5 - 18.0 4.7 - 6.0 42 - 52 78 - 100 27 - 31 32 - 36	mil/cu.mm % fL pg g/dL
13.5 - 18.0 4.7 - 6.0 42 - 52 78 - 100 27 - 31 32 - 36	mil/cu.mm % fL pg g/dL
4.7 - 6.0 42 - 52 78 - 100 27 - 31 32 - 36	mil/cu.mm % fL pg g/dL
42 - 52 78 - 100 27 - 31 32 - 36	mil/cu.mm % fL pg g/dL
78 - 100 27 - 31 32 - 36	% fL Pg g/dL
27 - 31 32 - 36	fL pg g/dL
32 - 36	pg g/dL
	g/dL
4000-10000	cell/cu.mm
40 - 80	%
20 - 40	%
2 - 10	%
	%
1-2	%
	10^3/ul
	fL
	%
	1 - 6 1-2 150 - 450 7.2 - 11.7 0.2 - 0.5 9.0 - 17.0

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST

HEALTHCARE SERV

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:47 PM

Sample ID:

Test Description	** * * * * * * * * * * * * * * * * * * *		21290
- Face	Value(s)	Reference Range	Unit
	LFT, Liver Fu	inction Test	
Bilirubin - Total Method : Serum, Jendrassik Grof	0.95	0.00 - 1.00	mg/dL
Bilirubin - Direct Method : Serum, Diazotization	0.20	0.00 - 0.20	mg/dL
Bilirubin - Indirect Method: Serum, Calculated	0.75	0.10 - 0.80	mg/dL
SGOT Method: Serum, UV with P5P, IFCC 37 degree	20.6	8 - 33	U/L
SGPT Method: Serum, UV with P5P, IFCC 37 degree	29.7	3 - 35	U/L
GGT-Gamma Glutamyl Transpeptidae Method : Serum, G-glutamyl-carboxy-nitoanilide	9.23	< 55	U/L
Alkaline Phosphatase Method: PNPP-AMP Buffer/Kinetic	117.3	53-128	U/L
otal Protein Method: Serum, Biuret, reagent blank end point	6.95	6.60 - 8.70	g/dL
albumin Method : Serum, Bromocresol green	3.88	3.50 - 5.30	g/dL
Hobulin Method : Serum, EIA	3.07	2.00-3.50	g/dL
/G Ratio Method : Serum, EIA	1.26	1.2 - 2.2	

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



A HEALTHCARE SERV

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:48 PM

Sample ID:

Test Description

Value(s)

Reference Range

Unit

/hpf /hpf /hpf

Urine(R/M) Routine Examination of Urine

C 1	Examination	
General	E.Vamination	-

Colour	PALE YELLOW	Pale Yellow
Transparency (Appearance)	CLEAR	Clear
Deposit	Absent	Absent
Reaction (pH)	Acidic 6.0	4.5 - 7.0
Specific gravity	1.015	1.005 - 1.030
Chemical Examination		-2000
T T 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		

Urine Protein (Albumin)	Absent	Absent
Urine Glucose (Sugar)	Present (++++)	Absent

Microscopic Examination

Examination		
Red blood cells	Absent	0-4
Pus cells (WBCs)	2 - 4 /HPF	0-9
Epithelial cells	2 - 3 /HPF	0-4
Crystals	Absent	Absent
Cast	Absent	Absent
Amorphous deposits	Absent	Absent
Bacteria	Absent	Absent
Trichomonas Vaginalis	Absent	Absent
Yeast cells	Absent	Absent

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST



Regd. No.: 1834

HEALTHCARE SERVI

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:48 PM

Sample ID:

Test Description

Value(s)

Reference Range

Unit

PSA (Prostate Specific Antigen)-Total

PSA- Prostate Specific Antigen*

0.98

0.0 - 3.5

ng/mL

INTERPRETATION:

Prostate-specific antigen (PSA) is a glycoprotein that is produced by the prostate gland, the lining of the urethra, and

bulbourethral gland. PSA exists in serum mainly in two forms, complexed to alpha-1-anti-chymotrypsin (PSA-ACT complex) and

unbound (free PSA). Increases in prostatic glandular size and tissue damage caused by benign prostatic hypertrophy, prostatitis, or

prostate cancer may increase circulating PSA levels. Transient increase in PSA can also be seen following per rectal digital or

sonological examinations.

Note: Patients on Biotin supplement may have interference in some immunoassays. With individuals taking high dose Biotin (more

than 5 mg per day) supplements, at least 8-hour wait time before blood draw is recommended.

Ref: Arch Pathol Lab Med-Vol 141, November 2017

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIÓLOGIST

Regd. No.: 1834

A HEALTHCARE SERV

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:49 PM

Sample ID:

Test Description			21290
Test Description	Value(s)	Reference Range	Unit
	Thyroid Profile	(T3, T4, TSH)	
T3-Total	0.98	0.87 - 2.73	
Method: CLIA		0.07 - 2.73	ng/dL
T4-Total	9.23	6.00	
Method: CLIA	9.23	6.09 - 12.23	ug/dL
TSH-Ultrasensitive	1.05	0.45	
Method: CLIA	1.03	0.45 - 4.50	uIU/mL
Interpretation			

Interpretation

TSH	Т3	T4	Suggested Interpretation for the Thyroid Function Tests Pattern	
Raised	Within range	Within range	Raised Within Range Within Range .Isolated High TSHespecially in the range of 4.7 to 15 m1U/m1 is commonly associated with Physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism.Intermittent 14 therapy for hypothyroidism .Recovery phase after Non-Thyroidal illness*	
Raised	Decreased	Decreased	Chronic Autoimmune Thyroiditis Post thyroidectomy, Post radioiodine Hypothyroid phase of transient thyroiditis"	
Raised or	_	Raised or	The Color	
within range	Raised	within range	Interfering antibodies to thyroid hormones (anti-TPO antibodies)Intermittent 14 therapy or T4 overdose interference- Amiodarone, Heparin,Beta blockers,steroids, anti-epileptics.	
Decreased	Raised or within range	Raised or within range	Isolated Low TSH -especially in the range of 0.1 to 0.4 often seen in elderly & Range Range associated with Non-Thyroidal illness .Subclinical Hyperthyroidism .Thyroxine ingestion'	
Decreased	Decreased	Decreased	Central Hypothyroidism .Non-Thyroidal illness .Recent treatment for Hyperthyroidism (TSH remains suppressed)"	
Decreased	Raised	Raised	Primary Hyperthyroidism (Graves' disease). Multinodular goitre, Toxic nodule •Transient thyroiditis: Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain's), Gestations thyrotoxicosis with hyperemesis gravidarum"	
Decreased Vithin Rang	Raised	Within range	T3 toxicosis *Non-Thyroidal illness	
Vithin range	Decreased	Within range	Isolated Low T3-often seen in elderly & associated Non-Thyroidal illness In elderly the drop in 13 level can be upto 25%.	

END OF REPORT

Lab technician

Dr.Kundan Kumar Sahoo CONSULTANT PATHOLOGIST / MICROBIOLOGIST

ZENA HEALTHCARE SERVICES

(A Unit of Zena Enterprises)

Patient Name: SASWAT TRIPATHY

Age / Gender: 52 years / Male

Patient ID: 18469

Referral: MEDI WHEEL

Collection Time: 18/10/2023, 10:42 AM

Reporting Time: 18/10/2023, 05:33 PM

Sample ID:

Value(s)	Reference Range	Unit
Glucose, Fas	sting (FBS)	
301.02	75 - 115	mg/dL
Glucose, Post	Prandial (PP)	
417.35	70 - 140	mg/dL
BUN, S	erum	
16.5	10 - 50	mg/dL
Creati	nine	
0.89	0.60 - 1.30	mg/dL
Blood Group ABO &	Rh Typing, Blood	
"O"		
Positive		
	Glucose, Fast 301.02 Glucose, Post 417.35 BUN, State 16.5 Creating 0.89 Blood Group ABO & "O"	Glucose, Fasting (FBS) 301.02 75 - 115 Glucose, Post Prandial (PP) 417.35 70 - 140 BUN, Serum 16.5 10 - 50 Creatinine 0.89 0.60 - 1.30 Blood Group ABO & Rh Typing, Blood "O"

ESR, Erythrocyte Sedimentation Rate

ESR - Erythrocyte Sedimentation Rate

9

0 - 15

mm/hr

Method : EDTA Whole Blood, Manual Westergren

Interpretation:

- It indicates presence and intensity of an inflammatory process. It does not diagnose a specific disease. Changes in the ESR are more significant than the abnormal results of a single test.
- It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, bacterial endocarditis, acute rheumatic fever, rheumatoid arthritis, SLE, Hodgkins disease, temporal arteritis and polymyalgia rheumatica.
- It is also increased in pregnancy, multiple myeloma, menstruation, and hypothyroidism.

END OF REPORT






SARVATTE BATHY SPIRES

SASWAT TRIPATHY,52YRS,, Sex Male DOB: ID:PAT000350

Acq. Date:18/10/2023 Acq. Time:10:59:18 Exp. Index:745



CHEST PA W: 3546, L: 2144 Tech ID:admin

Scale: 0.52
ZENA HEALTH CARE, BHUBANESWAR